Pfizer Calls for Guidance on Misleading Biosimilar-Related Communications

In a citizen petition filed Monday, Pfizer asked the FDA to issue draft guidance to prevent misleading communications by reference drug sponsors on the effectiveness of biosimilars.
Source: Drug Industry Daily